Das Stadtarchiv der Freien und Hansestadt Hamburg im Großen Brand von 1842

Das Staatsarchiv Hamburg feierte 2010 sein 300-jähriges Bestehen. Sein Vorläufer wurde bereits im Jahre 1293 erstmals erwähnt und somit die Aufbewahrung wichtiger Dokumente der Stadt an zentraler Stelle bezeugt. Doch erst seit dem 11. September 1710, dem Amtsantritt von Nicolaus Stampeel als wissenschaftlicher Archivar bei der Stadt Hamburg, werden Dokumente systematisch ausgewählt, bewahrt und erschlossen. Dieses Jubiläum hat das Staatsarchiv mit einem breit gefächerten Veranstaltungsprogramm begangen, zu dem auch Vorträge und Lesungen gehörten, die in der hier vorliegenden Festschrift abgedruckt sind.In 2010, the Hamburg State Archives celebrated its 300th anniversary. The Archives\u27 forerunner was first mentioned in 1293 and thus testified to the preservation of important documents of the city in a central place. But it was not until September 11th, 1710, when Nicolaus Stampeel took office as a scientific archivist at the City of Hamburg. From then on, documents were systematically selected, preserved and indexed. This anniversary was celebrated by the State Archives with a broad programme of events, which included lectures and readings printed in the commemorative volume available here

Veröffentlichungen aus dem Staatsarchiv der Freien und Hansestadt Hamburg

Das Staatsarchiv Hamburg feierte 2010 sein 300-jähriges Bestehen. Sein Vorläufer wurde bereits im Jahre 1293 erstmals erwähnt und somit die Aufbewahrung wichtiger Dokumente der Stadt an zentraler Stelle bezeugt. Doch erst seit dem 11. September 1710, dem Amtsantritt von Nicolaus Stampeel als wissenschaftlicher Archivar bei der Stadt Hamburg, werden Dokumente systematisch ausgewählt, bewahrt und erschlossen. Dieses Jubiläum hat das Staatsarchiv mit einem breit gefächerten Veranstaltungsprogramm begangen, zu dem auch Vorträge und Lesungen gehörten, die in der hier vorliegenden Festschrift abgedruckt sind.In 2010, the Hamburg State Archives celebrated its 300th anniversary. The Archives\u27 forerunner was first mentioned in 1293 and thus testified to the preservation of important documents of the city in a central place. But it was not until September 11th, 1710, when Nicolaus Stampeel took office as a scientific archivist at the City of Hamburg. From then on, documents were systematically selected, preserved and indexed. This anniversary was celebrated by the State Archives with a broad programme of events, which included lectures and readings printed in the commemorative volume available here

Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma - A randomized phase II/III trial of the German AIO and Italian GOIM

: This multicenter, randomized phase II/III study evaluated the addition of the vascular endothelial growth factor receptor-2 inhibitor ramucirumab to FLOT as perioperative treatment for resectable esophagogastric adenocarcinoma. Patients received either FLOT alone (Arm A) or combined with ramucirumab followed by ramucirumab monotherapy (Arm B). The primary endpoint for the phase II portion was the pathological complete or subtotal response (pCR/pSR) rate. Baseline characteristics were comparable between both arms with a high rate of tumors signet-ring cell component (A:47% B:43%). No between-arm difference in pCR/pSR rate was seen (A:29% B:26%), therefore the transition to phase III was not pursued. Nevertheless, the combination was associated with a significantly increased R0-resection rate compared to FLOT alone (A:82% B:96%; p=0.009). In addition, the median disease-free survival was numerically improved in Arm B (A:21 months B:32 months, HR 0.75, p=0.218), while the median overall survival was similar in both treatment arms (A:45 months B:46 months, HR 0.94, p=0.803). Patients with Siewert type I tumors receiving transthoracic esophagectomy with intrathoracic anastomosis showed an increased risk of serious postoperative complications after ramucirumab treatment, therefore recruitment of those patients was stopped after the first-third of the study. Overall, surgical morbidity and mortality was comparable, whereas more non-surgical grade≥3 adverse events were observed with the combination, especially anorexia (A:1% B:11%), hypertension (A:4% B:13%) and infections (A:19% B:33%). The combination of ramucirumab and FLOT as perioperative treatment shows efficacy signals, particularly in terms of R0 resection rates, for a study population with a high proportion of prognostically poor histological subtypes, and further evaluation in this subgroup seems warranted. This article is protected by copyright. All rights reserved